What is Arcturus Therapeutics Holdings Pre-Tax Income?
Pretax income is the income that a company earns before paying income taxes. Arcturus Therapeutics Holdings's pretax income for the
three
months ended in Dec. 2023 was $-11.4 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-27.9 Mil.
Arcturus Therapeutics Holdings's pretax margin was -45.64%.
During the past 13 years, Arcturus Therapeutics Holdings's highest Pretax Margin was 5.17%. The lowest was -1647.98%. And the median was -83.87%.
Arcturus Therapeutics Holdings Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Arcturus Therapeutics Holdings Pre-Tax Income Chart
Competitive Comparison of Arcturus Therapeutics Holdings's Pre-Tax Income
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Pre-Tax Income falls into.
Arcturus Therapeutics Holdings Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings (NAS:ARCT) Pre-Tax Income Explanation
Arcturus Therapeutics Holdings's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Arcturus Therapeutics Holdings's highest Pretax Margin was 5.17%. The lowest was -1647.98%. And the median was -83.87%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARCT has been successfully added to your 